{
    "items": [
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/let2019s-just-get-married-2013-the-story-of-an-acquisition\" title=\"Let\u2019s just get married \u2013 the story of an acquisition\" class=\"state-published\">Let\u2019s just get married \u2013 the story of an acquisition</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=bioescalator-news\" title=\"BioEscalator news\">\n                        <span class=\"badge bg-primary\">BioEscalator news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">5 Mar, 2026</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">\"We decided to skip the engagement and just get married\" \u2013 that\u2019s how Hutano Diagnostics\u2019 CEO Atherton Mutombwera describes his company\u2019s acquisition by EDx Medical in 2023. The meeting of minds between him and the purchaser\u2019s CEO, Dr Mike Hudson, was the culmination of six years of hard work by Atherton developing multiplex lateral flow diagnostics based on aptamers.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-awarded-20ac8-million-in-horizon-europe-2025-grant-funding-to-advance-phase-2-study-of-theo-260-in-ovarian-cancer\" title=\"Theolytics awarded \u20ac8 million in Horizon Europe 2025 grant funding to advance phase 2 study of THEO-260 in ovarian cancer\" class=\"state-published\">Theolytics awarded \u20ac8 million in Horizon Europe 2025 grant funding to advance phase 2 study of THEO-260 in ovarian cancer</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">4 Mar, 2026</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">Pending final negotiations, the grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer. The competitive funding award highlights Theolytics\u2019 innovative science and strong clinical development plan. The application is coordinated with several major international clinical centres and world-class partners.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/cyanocapture-and-persist-ai-announce-strategic-collaboration-to-build-worlds-first-robotic-gmp-facility-for-oral-protein-and-peptide-drugs\" title=\"CyanoCapture and Persist AI announce strategic collaboration to build world's first robotic GMP facility for oral protein and peptide drugs\" class=\"state-published\">CyanoCapture and Persist AI announce strategic collaboration to build world's first robotic GMP facility for oral protein and peptide drugs</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">18 Feb, 2026</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">The pioneering partnership combines cyanobacteria-based oral delivery with AI-driven robotics to transform how life-saving biologics reach patients.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-appoints-experienced-biotech-executive-dr-michelle-morrow-as-chief-scientific-officer\" title=\"Nucleome Therapeutics appoints experienced biotech executive Dr Michelle Morrow as Chief Scientific Officer\" class=\"state-published\">Nucleome Therapeutics appoints experienced biotech executive Dr Michelle Morrow as Chief Scientific Officer</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">16 Feb, 2026</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">Dr Morrow brings deep expertise in immunology, oncology, and pharmacology, with a strong track record of advancing innovative pipelines from discovery to the clinic. The appointment reflects growing momentum at Nucleome following the nomination of the first preclinical development candidate, lead candidate NTP464, which is progressing towards IND-enabling studies.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-jonathan-montagu-as-chair-of-the-board-of-directors\" title=\"OMass Therapeutics appoints Jonathan Montagu as Chair of the Board of Directors\" class=\"state-published\">OMass Therapeutics appoints Jonathan Montagu as Chair of the Board of Directors</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">28 Jan, 2026</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announced updates to its Board of Directors, including the appointment of Jonathan Montagu, Chief Executive Officer and co-founder of HotSpot Therapeutics, as Board Chair.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/certis-belchim-and-moa-sign-strategic-collaboration-deal\" title=\"Certis Belchim and Moa sign strategic collaboration deal\" class=\"state-published\">Certis Belchim and Moa sign strategic collaboration deal</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">8 Jan, 2026</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">Netherlands-based company becomes Moa's third major commercial partner in 18 months.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-enters-2026-with-dark-antigen-licensing-to-boehringer-ingelheim-appointment-of-chief-medical-officer-and-plans-to-advance-darkfox-t-cell-engager-into-first-in-human-studies\" title=\"Enara Bio enters 2026 with Dark Antigen licensing to Boehringer Ingelheim, appointment of Chief Medical Officer and plans to advance DARKFOX T-cell engager into First-in-Human studies\" class=\"state-published\">Enara Bio enters 2026 with Dark Antigen licensing to Boehringer Ingelheim, appointment of Chief Medical Officer and plans to advance DARKFOX T-cell engager into First-in-Human studies</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">8 Jan, 2026</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">Boehringer Ingelheim has licensed additional Dark Antigens from various tumour types, enhancing Enara\u2019s eligibility for milestone payments under their collaboration. Scott Drutman, M.D., Ph.D. has been appointed as Chief Medical Officer, bringing valuable expertise in translational medicine and immuno-oncology. Enara\u2019s ENA101, a bispecific T-cell engager targeting the DARKFOX antigen, is planned to enter First-in-Human studies in 2026, while the company continues expanding its EDAPT discovery platform to include cell-surface Dark Antigens.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-nominates-first-preclinical-development-candidate\" title=\"Nucleome Therapeutics nominates first preclinical development candidate\" class=\"state-published\">Nucleome Therapeutics nominates first preclinical development candidate</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">7 Jan, 2026</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases. Evolution of Nucleome\u2019s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/abbott-to-acquire-exact-sciences\" title=\"Abbott to acquire Exact Sciences\" class=\"state-published\">Abbott to acquire Exact Sciences</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">20 Nov, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/prior-labs-and-oxford-cancer-analytics-partner-to-advance-liquid-biopsy-and-clinical-decision-making-in-lung-disease\" title=\"Prior Labs and Oxford Cancer Analytics partner to advance liquid biopsy and clinical decision making in lung disease\" class=\"state-published\">Prior Labs and Oxford Cancer Analytics partner to advance liquid biopsy and clinical decision making in lung disease</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">19 Nov, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">Prior Labs is collaborating with Oxford Cancer Analytics (OXcan) to apply TabPFN to high-clinical-need lung diseases, focusing on more accurate differentiation across complex disease stages.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/ochre-bio-completes-human-liver-functional-genomics-and-single-cell-datasets-in-partnership-with-gsk\" title=\"Ochre Bio completes human liver functional genomics and single-cell datasets in partnership with GSK\" class=\"state-published\">Ochre Bio completes human liver functional genomics and single-cell datasets in partnership with GSK</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">18 Nov, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, today announced the successful completion of the research phase of its collaboration with GSK, delivering two comprehensive functional genomics and single-cell human liver datasets.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-announces-issuance-of-u-s-patent-for-proprietary-pgn-edodm1-molecule\" title=\"PepGen announces issuance of U.S. Patent for proprietary PGN-EDODM1 molecule\" class=\"state-published\">PepGen announces issuance of U.S. Patent for proprietary PGN-EDODM1 molecule</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">12 Nov, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">The Composition of Matter patent covers the Company\u2019s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-founder-professor-james-davies-and-oxford-university-publish-paper-in-prestigious-journal-cell\" title=\"Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell\" class=\"state-published\">Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">6 Nov, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the first time, pioneering a new approach to identify new drug targets from human genetics.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio2019s-darkfox-discovery-propels-ena101-the-first-ever-bispecific-t-cell-engager-targeting-a-cancer-specific-dark-antigen-into-ind-enabling-studies\" title=\"Enara Bio\u2019s DARKFOX discovery propels ENA101, the first ever bispecific T Cell engager targeting a cancer-specific dark antigen, into IND-enabling studies\" class=\"state-published\">Enara Bio\u2019s DARKFOX discovery propels ENA101, the first ever bispecific T Cell engager targeting a cancer-specific dark antigen, into IND-enabling studies</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">4 Nov, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens\u00ae and the development of bispecific T cell engagers for solid tumours, will unveil its newly discovered cancer-specific target DARKFOX\u2122 as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in National Harbor, MD.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/partnership-with-cyanocapture-ltd-to-develop-bionanotechnology-for-targeted-drug-delivery\" title=\"Partnership with CyanoCapture Ltd to develop bionanotechnology for targeted drug delivery\" class=\"state-published\">Partnership with CyanoCapture Ltd to develop bionanotechnology for targeted drug delivery</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">31 Oct, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based targeted drug delivery systems, exploiting unique traits found in fast-growing cyanobacteria.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alethio-therapeutics-launches-with-new-ceo-and-chair-to-advance-two-targeted-medicines-for-myeloproliferative-neoplasms-chronic-blood-cancers\" title=\"Alethio Therapeutics launches with new CEO and Chair to advance two targeted medicines for Myeloproliferative Neoplasms (Chronic Blood Cancers)\" class=\"state-published\">Alethio Therapeutics launches with new CEO and Chair to advance two targeted medicines for Myeloproliferative Neoplasms (Chronic Blood Cancers)</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">30 Oct, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">Leveraging deep scientific and clinical expertise in MPNs, the company aims to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells. Progress is being made with AT-01, a first-in-class antibody-drug conjugate (ADC) program, which has strong preclinical validation and is advancing toward IND/CTA-enabling studies anticipated to start in the first half of 2026. Additionally, AT-02 expands the ADC portfolio by targeting mutant CALR, a key driver mutation in MPNs. The leadership and board have been strengthened with the appointments of Dr. Rohit Batta as CEO and Mike Grey as Chair.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/medimabbio-secures-krw-25-6b-in-series-b-funding-to-advance-pipeline-and-global-partnerships\" title=\"MediMabBio secures KRW 25.6B in Series B funding to advance pipeline and global partnerships\" class=\"state-published\">MediMabBio secures KRW 25.6B in Series B funding to advance pipeline and global partnerships</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">24 Oct, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">MediMabBio has successfully raised KRW 25.6B (USD $17M) in its Series B financing round. The newly secured capital will be used to expand strategic global partnerships for accelerated business development and the advancement of follow-on programs.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/medimabbio-wins-1st-place-at-japan2019s-201cinnovation-tiger-2025201d\" title=\"MediMabBio Wins 1st Place at Japan\u2019s \u201cInnovation Tiger 2025\u201d\" class=\"state-published\">MediMabBio Wins 1st Place at Japan\u2019s \u201cInnovation Tiger 2025\u201d</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">13 Oct, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">MediMabBio won first place at Innovation Tiger 2025, a global biotech startup competition held at Shonan iPark in Japan. The final round featured 16 companies selected from 79 applicants across Korea, Japan, and Taiwan.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-appoints-experienced-medical-oncologist-matilde-saggese-md-as-chief-medical-officer\" title=\"Theolytics appoints experienced medical oncologist Matilde Saggese, MD, as Chief Medical Officer\" class=\"state-published\">Theolytics appoints experienced medical oncologist Matilde Saggese, MD, as Chief Medical Officer</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">7 Oct, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260. THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer.</p>\n        \n\n                              \n        \n    </div>\n\n\n",
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n         \n        <h4>\n            <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-announces-highest-mean-splicing-correction-reported-in-dm1-patients\" title=\"PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients\" class=\"state-published\">PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients</a>\n        </h4>\n        \n        \n            \n\n    \n\n        <ul class=\"list-unstyled list-inline categories-list\">\n            \n            \n                <li class=\"list-inline-item\">\n                    <a href=\"https://www.bioescalator.ox.ac.uk/search?categories=alumni-news\" title=\"Alumni news\">\n                        <span class=\"badge bg-primary\">Alumni news</span>\n                    </a>\n                </li>\n            \n\n        </ul>\n\n    \n\n\n        \n\n        \n            <p class=\"details\" itemprop=\"datePublished\">24 Sep, 2025</p>\n        \n                        \n        \n            <p data-truncate=\"yes\" data-truncate-lines=\"2\">53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing. PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity</p>\n        \n\n                              \n        \n    </div>\n\n\n"
    ],
    "more": "\n\n    \n        <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news&amp;random=64749152-1385-4183-a4ff-fc719209a03e&amp;b_start:int=40&amp;categories=alumni-news&amp;format=json&amp;r=29908178\" title=\"Load more\" class=\"btn load-more-button\">\n            Load More\n        </a>\n    \n\n\n",
    "msg": ""
}